Biosimilar Manufacturing Strategies

With over 20,000 readers, Contract Pharma is a monthly magazine and online publication dedicated to the pharmaceutical and biopharmaceutical industries. More specifically, it focuses on the evolution of the outsourcing industry, covering changing regulations and new business models.

George I’ons, Head of Product Strategy and Insights, discusses the current opportunities for biosimilar manufacturers in the latest edition of Contract Pharma.

He examines the potentially decisive factors that could encourage or discourage switching for injectable combination products. These range from the confidence in biosimilar products, trust in the ancillary drug delivery device, safety and regulations, evidence of human factors studies and finally, proven manufacturability and durability. Read the full article to find out more.